Skip to main content
OpenTrials
Completed

NCT Number: NCT04094558

Validation of the Small Intestine Microbiome Aspiration (SIMBA) Capsule

Prospective, open label trial to establish the ability of the SIMBA Capsule to accurately obtain a sample from the small bowel of participants with IBS (10 constipation-predominant (IBS-C) and 10 diarrhea-predominant (IBS-D)) and healthy participants (n=10). The accuracy of targeting the small bowel will be established by visual confirmation via X-ray. The clinical utility of the collected sample will be evaluated by analysis with samples obtained by the current gold standard (duodenal aspirate), as well as stool analysis and LBT.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cumming School of Medicine, University of Calgary

Calgary, Alberta, T2N 4Z6, Canada

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged between 18 and 70 years.
  • Diagnosis of IBS by Rome 4 criteria (IBS groups) or no previous diagnosis of IBS or suspected IBS (Control group).
  • Ability to understand and provide informed consent.
  • Ability and willingness to meet the required schedule and study interventions.
  • No planned change in diet or medical interventions during the study duration.
  • Adequate mobility to transfer repeatedly between X-ray (standing or lying), and waiting (sitting).
  • Willing and able to undergo a sedated esophagogastroduodenoscopy (EGD) with aspirate and brushing.

Exclusion criteria

  • Prior gastrointestinal disease, surgery, or radiation treatment which, in the investigator's opinion, would lead to intestinal structuring or obstruction with a risk of capsule non-excretion (particular diseases which would be assessed on a case-by-case basis would include, achalasia, eosinophilic esophagitis, Crohn's disease, cancer diagnosis or treatment within the past year, or previous esophageal, gastric, small intestinal, or colonic surgery. Appendectomy or cholecystectomy more than 3 months prior to enrollment are acceptable).
  • Use of any medications in the previous week that could substantially alter gastrointestinal motor function (e.g., opioids, prokinetics, anticholinergics, laxatives), or acidity (PPI, H2RA).
  • History of oropharyngeal dysphagia or other swallowing disorder with a risk of aspiration of the capsule.
  • Females of childbearing age who are not practicing birth control and/or are pregnant or lactating.
  • No antibiotics, or colon cleanses/bowel prep for 2 weeks.
  • < 2 bowel movements per week (Control Group).

Treatment and study plan

Ingestible Capsule

Device

Participants will swallow capsules and collect in stool concurrent with stool samples

Sedated EGD

Procedure

Participants will undergo sedated esophagogastroduodenoscopy (EGD) for collection of small intestine aspirate and simultaneous saliva sample.

Lactulose breath test

Diagnostic Test

Hydrogen and methane breath test with lactulose substrate

Primary outcomes

  1. Bacterial composition

    Time frame: same day

    • Correlations of bacterial composition (superimposability of PLS-DA mapping) of samples collected by the SIMBA Capsule compared to small bowel aspirate and to mucosal microbiome sample obtained by brushing. (hypothesis: findings will be similar)
  2. Bacterial composition

    Time frame: same day

    • Correlations of bacterial composition (superimposability of PLS-DA mapping) of samples collected by the SIMBA Capsule compared to stool sample obtained at same time. (hypothesis: findings will be different)

Secondary outcomes

  1. Bacterial composition

    Time frame: within 5 days of primary measures

    • Correlation of hydrogen- and methane-producing bacteria species (by 16s RNA sequencing) found by SIMBA Capsule with hydrogen and methane concentrations (peak and rise in ppm) detected by LBT and bacterial density (CFU/ml) of endoscopic aspirate.

Sponsors and collaborators

Lead sponsor

University of Calgary

Other

Collaborators

  • Nimble Science Ltd.

Registry information

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Sep 19, 2019
Registry last updated
Sep 2, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.